Clinical Trial Update: Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

View source ↗

Summary

This clinical trial update describes an expanded access program for Ivosidenib in relapsed/refractory IDH1-mutant acute myeloid leukemia. It notes that the prod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Ivosidenib (ivosidenib)

Snippet

Sponsor: Agios Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia, Relapsed Adult AML | Status: APPROVED_FOR_MARKETING